FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 206 filers reported holding FATE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.69 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $3,121 | -100.0% | 309,359 | -0.6% | 0.02% | -57.4% |
| Q3 2022 | $6,977,000 | +45.4% | 311,331 | +60.8% | 0.05% | +54.3% |
| Q2 2022 | $4,798,000 | -31.5% | 193,637 | +7.2% | 0.04% | -14.6% |
| Q1 2022 | $7,003,000 | -32.9% | 180,620 | +4.0% | 0.04% | -24.1% |
| Q4 2021 | $10,434,000 | +24.0% | 173,704 | +22.4% | 0.05% | +17.4% |
| Q3 2021 | $8,413,000 | -31.7% | 141,951 | 0.0% | 0.05% | -39.5% |
| Q2 2021 | $12,320,000 | +561.3% | 141,951 | +528.1% | 0.08% | +533.3% |
| Q1 2021 | $1,863,000 | -9.3% | 22,600 | 0.0% | 0.01% | -14.3% |
| Q4 2020 | $2,055,000 | +576.0% | 22,600 | +197.4% | 0.01% | +600.0% |
| Q3 2020 | $304,000 | -62.9% | 7,600 | -68.2% | 0.00% | -71.4% |
| Q2 2020 | $820,000 | – | 23,900 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $197,709,000 | 22.51% |
| Redmile Group, LLC | 12,957,222 | $758,127,000 | 17.24% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $60,690,000 | 6.28% |
| Casdin Capital, LLC | 3,400,000 | $198,934,000 | 5.61% |
| Ally Bridge Group (NY) LLC | 270,000 | $15,798,000 | 5.52% |
| DAFNA Capital Management LLC | 372,160 | $21,775,000 | 5.48% |
| Tri Locum Partners LP | 142,032 | $8,310,000 | 3.27% |
| Kynam Capital Management, LP | 95,561 | $5,591,000 | 2.99% |
| Artal Group S.A. | 1,800,000 | $105,318,000 | 2.86% |
| Bellevue Group AG | 3,775,736 | $220,918,000 | 2.28% |